Profiting from a Bearish Bet on Commodities

Nicholas Vardy

Nicholas Vardy has a unique background that has proven his knack for making money in different markets around the world.

It was a terrible week in global stock markets with the Dow Jones down 2.74%, the S&P 500 tumbling 3.14% and the NASDAQ dropping 4.45%. Surprisingly, the MCSI Emerging Markets Index was down only 1.87%.

You were stopped out of three positions in your Bull Market Alert portfolio: Flextronics International (FLEX), United Rentals, Inc. (URI) and the iShares Transportation Average (IYT), all at a loss.

The market pullback was worse than I anticipated. Market sentiment actually ranked a “1” on my favorite summary of these indicators — the lowest I have ever seen.

If you’re a diehard contrarian, this is the time to “buy, buy, buy” in anticipation of a sharp snapback.

That said, this week I am not going to recommend for you to do that.

This week’s Bull Market Alert recommendation switches gears to try to seek to profit from prices going down through a bearish bet on commodities by (shorting) selling the PowerShares DB Commodity Index Tracking Fund (DBC).

DBC is the largest commodity-related exchange-traded fund (ETF) and tracks a broad basket of the 14 most heavily traded commodities. These include Light Sweet Crude Oil (WTI), Heating Oil, RBOB Gasoline, Natural Gas, Brent Crude, Gold, Silver, Aluminum, Zinc, Copper Grade A, Corn, Wheat, Soybeans and Sugar.

As the chart below confirms, commodities in general, and DBC in particular, have entered into a freefall since the start of September.

DBC_101314

Brent Crude dropped almost 24% since midsummer, despite perennial unrest in the Middle East, thanks in part to increased production of shale oil in the United States. The Bloomberg industrial metals index is down 37% from its post-crisis high. Gold is down 38% since its high in 2011. Even U.S. farmers are harvesting a bumper crop year, with record corn and soybean crops pushing the prices of those agricultural commodities down.

Exclusive  Four Construction Equipment Infrastructure Stocks to Buy Rev up Growth Engines

Here’s why I think commodities prices are set to fall further.

First, the much-vaunted commodities super cycle is over. I wrote about the end of that boom back in 2012. After meandering in a trading range, the collapse of commodity prices really started to accelerate since the start of September.

Second, global demand for commodities is dropping as much of the world’s economy is sluggish. The International Monetary Fund (IMF) recently cut its global growth forecasts for 2014 and 2015.

The IMF announced it expected global growth to be 3.3% in 2014, 0.4 percentage points lower than in April and 0.1 points down on interim forecasts made in July.

Third, don’t expect China to jump into the breach as it has in the past. It turns out a good chunk of China’s commodity demand was due to a bit of financial engineering known as the “collateral trade.” Commodities of all types shipped to China have been used as collateral via the shadow banking system to finance other investments offering higher returns — in particular, property. Instead of being used for something productive, many commodities have been stockpiled with over 100 million tons of iron ore tied up in finance deals.

You can short commodities directly by buying the ProShares UltraShort Bloomberg Commodity (CMD). But that is a small and illiquid ETF and is not my formal recommendation this week.

It is better to just short (sell) PowerShares DB Commodity Index Tracking Fund (DBC) and profit as that continues its downward trend. Set your buy back stop on DBC at $23.75.

Exclusive  Exchange-Traded Funds (ETFs) vs. Stocks; Differences, Pros and Cons

If you want to play the options, buy the January $23.00 DBC put options (DBC150117P00023000), which will rise in value as the price of DBC falls.

Portfolio Update

Visa Inc. (V) lost 3.31% last week. It was a week where the Dow Jones Industrial Average itself lost 2.74%. Visa was one of the “better houses on a bad street” last week. Visa will report earnings on Oct. 29, after markets close. V is a HOLD.

Gilead Sciences Inc. (GILD) fell 2.62%. The Food and Drug Administration cleared GILD’s new hepatitis C cure, Harvoni, last Friday. This medication could be used for the treatment of over three million cases of this disease and costs $1,125 per pill. A typical treatment regime is 12 weeks, or $94,500. Harvoni’s “sister pill,” Sovaldi, fetched $5.8 billion in sales for the first half of 2014. Harvoni will likely be another huge win for GILD’s bottom line. GILD is expected to report earnings on Oct. 28, after markets close. GILD remains a BUY.

Bank of Ireland (IRE) tumbled 8.84% last week as investors threw the baby out with the bathwater in selling risk assets across the board. With the Irish economy now recording rates of economic growth not seen since its days as the “Celtic Tiger,” this sell-off is about as unwarranted as you can see. Still trading below its 50-day moving average, Bank of Ireland is a HOLD.

Nicholas Vardy

P.S. Join Me for the World MoneyShow London, Nov. 7-8

I invite you to join me for The World MoneyShow in London, Nov. 7-8, at the Queen Elizabeth II Conference Centre. I will be presenting on Saturday, Nov. 8, 3:30 – 4:30 pm. Register at no charge by calling 1-800-970-4355 and identify yourself as a Nicholas Vardy subscriber by mentioning code 036913 or by clicking this link and following the instructions.

Like This Article?
Now Get Our FREE Special Report:
Alternative Investing: Investing in Timber

Stock Investor editor Paul Dykewicz reveals why investing in timber may be one of the best long-term portfolio strategies you'll find today.

Get Access to the Report, 100% FREE


img
previous article

Flint’s Diplomat Pharmacy (NYSE: DPLO) gained the spotlight when it completed a successful public stock offering (IPO) on Oct. 10 to raise funds to expand its operations, despite its home base in a place that naysayers have characterized as something akin to a hell hole.

PREMIUM SERVICES FOR INVESTORS

Dr. Mark Skousen

Named one of the "Top 20 Living Economists," Dr. Skousen is a professional economist, investment expert, university professor, and author of more than 25 books.

Product Details

  • Forecasts & Strategies
  • Home Run Trader
  • Fast Money Alert
  • Five Star Trader
  • TNT Trader
LEARN MORE HERE

Bryan Perry

A former Wall Street financial advisor with three decades' experience, Bryan Perry focuses his efforts on high-yield income investing and quick-hitting options plays.

Product Details

  • Cash Machine
  • Premium Income (exclusively for subscribers of Cash Machine)
  • Quick Income Trader
  • Breakout Profits Alert
  • Hi-Tech Trader
LEARN MORE HERE

Jim Woods

Jim Woods has over 20 years of experience in the markets from working as a stockbroker,
financial journalist, and money manager. As well as a book author and regular contributor to
numerous investment websites, Jim is the editor of:

Product Details

  • Successful Investing
  • Intelligence Report
  • Bullseye Stock Trader
LEARN MORE HERE

Bob Carlson

Bob Carlson provides independent, objective research covering all the financial issues of retirement and retirement planning. In addition, Bob serves as Chairman of the Board of Trustees of the Fairfax County (VA) Employees’ Retirement System, which has over $2.8 billion in assets.

Product Details

  • Retirement Watch
  • Retirement Watch Spotlight Series
  • Lifetime Retirement Protection Program
LEARN MORE HERE

Jon Johnson

Jon Johnson's philosophy in investing and trading is to take what the market gives you regardless if that is to the upside or downside. For the past 21 years, Jon has helped thousands of clients gain success in the financial markets through his newsletters and education services:

Product Details

  • Investment House Daily
  • Technical Traders Alert
  • Success Trading Group
LEARN MORE HERE

DividendInvestor.com

Used by financial advisors and individual investors all over the world, DividendInvestor.com is the premier provider and one-stop shop for dividend information and research.

Product Details

Popular tools include our proprietary Dividend Calendar, Dividend Calculator, Dividend Score Card, and many more.

  • Dividend Investor
LEARN MORE HERE